INTRODUCTION
Classical Hodgkin Lymphoma (cHL) is a unique subtype of lymphoma, in which the 9 0 malignant Hodgkin Reed-Sternberg (HRS) cells represent only a small proportion of the overall tumor cellularity (1-5%). 1 The tumor microenvironment (TME) is predominantly composed of inflammatory cells, including macrophages, CD4+ and CD8+ T cells, plasma cells, eosinophils, and other immune cells, yet anti-tumor immunity fails to effectively recognize and eliminate the malignant cells. HRS cells achieve immune evasion by multiple 9 5
mechanisms including enhanced expression of programmed cell death-1 ligands (PD-L1 and PD-L2) that bind PD-1 (CD279) on the surface of antigen-experienced T-cells to suppress Tcell activation, and diminished or absent expression of MHC Class I to prevent recognition by the adaptive immune response.
2-5 1 0 0
The critical role for PD-1:PD-1 ligand interactions in cHL was established with recent trials of monoclonal antibodies directed against PD-1. 6-8 Treatment with nivolumab, a fully human IgG4 antibody, in a phase I study resulted in an overall response rate (ORR) of 87% and complete remission (CR) rate of 17% in a series of patients with multiply relapsed/refractory cHL. 6 In an expanded phase II trial, comprising patients with relapsed/refractory disease 1 0 5
following brentuximab vedotin and stem cell transplant, an objective response was seen in 66.3% of patients, with a progression-free survival (PFS) at 6 months of 76.9%, including patients with durable remissions. Importantly, patients with the highest PD-L1 expression among HRS cells had the best clinical response. 7 Similar clinical response rates were found in trials of pembrolizumab, a distinct antibody which also targets PD-1. PD-1 ligand expression by HRS cells is attributable, in large part, to characteristic copy gains of chromosome 9p24.1, which includes the PD-L1, PD-L2, and JAK2 loci, and results in a direct increase in PD-L1 and PD-L2 transcripts and proteins, and an indirect increase due to augmented JAK-STAT signaling. 2, 3 Critically, high level PD-L1/ PD-L2 copy gains 1 1 5
(amplification) in HRS cells is associated with advanced stage disease and an inferior outcome following standard induction therapy. 3 However, not all PD-L1 protein within the cHL TME is associated with HRS cells. We have shown that PD-L1 is also expressed by tumor-associated macrophages (TAMs) . 10 This observation is of interest, as increased TAMs and a macrophage-related gene expression signature predict poor clinical response to 1 2 0 combination chemotherapy in patients with advanced stage disease. 11 The number of TAMs that express PD-L1, the relative contribution of TAMs and HRS cells to the overall pool of PD-L1 in the TME, and the geographic distribution of PD-L1 expressing cells within the TME are undefined. Similarly, the numbers and types of T-cells that express PD-1 and their geographic distribution are unknown, despite the striking clinical effectiveness of PD-1 1 2 5
blockade.
METHODS

Tissue Samples
3 0
Formalin-fixed, paraffin embedded (FFPE) whole tissues from tumors were derived from the archives of Brigham & Women's Hospital, Boston, with IRB approval (2014P001721) . Hematoxylin & eosin (H&E) stained tissue sections and the original diagnostic reports were reviewed by an expert hematopathologist (SR). Twenty cases were selected for the study, based on the availability of high quality, whole lymph node excision biopsy tissue (12 EBV 1 3 5
negative; 8 EBV positive), including nodular sclerosing (NSHL, n=11), mixed cellularity (MCHL, n=6), lymphocyte rich (LRCHL, n=1), and cHL, not otherwise specified (cHL, NOS, n=2) subtypes (Supplementary 12 The decisions made by the software can be over-ruled to improve accuracy, until phenotyping is optimized. Unique phenotyping was performed for each tumor, and then applied to both tiled study images to account for inter-sample variability of signal intensities. Thresholds for "positive" staining and the accuracy of phenotypic algorithms were confirmed by the pathologist (SR) for each case. Inform (PerkinElmer) 1 8 5
automatically derives maps of cell membranes and Cartesian coordinates for each phenotyped cell within the image.
Quantification of the microenvironment
The shortest Euclidian distance from each cell of one phenotype ("A") towards the nearest 1 9 0 cell of a second phenotype ("B") was calculated using the Cartesian coordinates. These minimum distances from each cell of type A were then averaged to calculate the average nearest neighbor distance between cell type A and B (NN AB ).
Physical interactions between two cells were determined based on the membrane maps that total PD-L1 staining (calculated as percentage of total fluorescence units), and found that, for every case, TAMs contributed the majority of PD-L1 in the tumor microenvironment (TME) ( Figure 1B ). A mean of 78.5% of the total PD-L1 expression within the TME was contributed by TAMs across the series (range 50.4 -98.5%; S.D. = 14.8). and the distances from each PD-L1-TAM to the nearest PD-L1+ HRS cell ( Figure 2D ). In all 20 cases, the mean distance from PD-L1+ TAMs to the nearest PD-L1+ HRS cell was significantly less than the mean distance from PD-L1-TAMs to the nearest PD-L1+ HRS cell ( Figure 2E ). This difference was highly significant across the case series (p< 0.0001, paired t-test). Conversely, the mean distance from PD-L1+ HRS cells to PD-L1+ TAMs was shorter Figure 2G) . This difference was also highly significant across the case series (p=0.0002, paired t-test).
RESULTS
Cell
To ensure the specificity of the analysis, we also optimized IF staining for CD163, a 2 3 5 macrophage marker with a more restricted expression pattern than CD68 (Supplementary Figure 3) . We found that the majority of cells with positive staining for CD68 were also positive for CD163, as expected . By quantitative analysis, we found that the mean distance from PD-L1+ CD68+ CD163+ TAMs to the nearest PD-L1+ HRS cell was significantly less than the mean distance from PD-L1-CD68+ CD163+ TAMs 
PD-1+ T-cells in relation to PD-L1+ TAMs
Visual inspection and cell phenotyping revealed that a subset of PD-1+ cells within the cHL TME are CD4+ and that these cells appeared enriched in the vicinity of PD-L1+ TAMs (exemplified by case N10, Figure 3A ; B). Quantitative analysis revealed that the mean 2 6 0 distance from PD-1+ CD4+ T-cells to the nearest PD-L1+ TAM was less than the mean distance from PD-1+ CD4+ T-cells to the nearest PD-L1-TAM in 16 of 20 cases ( Figure 3C ). This difference in distances was highly significant across the case series (p=0.004; Figure  3C ). Similarly, we observed that the mean distance from PD-1+ CD8+ T-cells to the nearest PD-L1+ TAM (exemplified by case P6, Figure 3D ; E) was less than the mean distance from 2 6 5
PD-1+ CD8+ T-cells to the nearest PD-L1-TAM in 15 of 20 cases ( Figure 3F ). This difference was highly significant for the series (p=0.005) and, overall, consistent with coordinate regional localization of PD-1+ T-cells and PD-L1+ TAMs. The mean distance from PD-1+ T-cells to PD-L1+ TAMs was also weakly, but positively correlated with the mean distance from PD-L1+ TAMs to PD-L1+ HRS cells for the series (r=0.269 for CD4+ T-2 7 0 cells and r=0.283 for CD8+ T-cells, respectively).
PD-1+ T-cells in relation to PD-L1+ HRS cells
We further wished to determine whether PD-1+ T-cells were preferentially oriented in proximity to PD-L1+ HRS cells. Quantitative analysis revealed that the mean distance from Figure 6F) . The difference did not reach significance for the series (p=0.1).
T-cells in direct contact with TAMs
Close visual inspection of stained tissue sections indicated PD-1+ expression on a subset of 2 8 5
CD4+ T-cells and a subset of CD8+ T-cells in direct contact with TAMs ( Figure 4A -D). CD4+ T-cells were more likely than CD8+ T-cells to be in direct contact with TAMs across the series (28% [95% CI 22%-34%] versus 7% [95% CI 6%-9%], respectively, Figure 4E ). Moreover, CD4+ T-cells and CD8+ T-cells, as proportions of the cellularity, were both significantly higher at the points of contact with TAMs than at points without contact (>75 µm 2 9 0 distant; p =0.01 and < 0.01, respectively; Figure 4E ). cellularity, were significantly higher at the points of contact with PD-L1+ TAMs than at points without contact (>75 µm distant; p= 0.04 and <0.01, respectively; Figure 4F ) consistent with the notion that PD-1+ CD4+ T-cells and PD-1+ CD8+ T-cells in contact with PD-L1+ TAMs are a locally enriched population.
PD-1+ CD4+ T-cells also exceeded PD-1+ CD8+ T-cells in contact with
0 0 T-cells in direct contact with HRS cells
We also observed PD-1 on subsets of CD4+ T-cells and CD8+ T-cells in direct contact with HRS cells (Figure 5A-D Figure 5E ). CD4+ T-cells, as proportions of the cellularity, were 3 0 5 significantly higher at the points of contact with HRS cells than at points without contact (p <0.01; Figure 5E ). In contrast, CD8+ T-cells, as proportions of the cellularity, were not Figure 5F ). Like CD4+ T-cells in general, PD-1+ CD4+ T-cells were a higher proportion of the cellularity at the points of contact with PD-L1+ HRS than at points without 3 1 5
contact (p< 0.01; Figure 5F ). In contrast, the proportion of PD-1+ CD8+ T-cells was not significantly different between the points of contact with PD-L1+ HRS cells and at points without contact (p= 0.37; Figure 5F ), consistent with the notion that PD-1+ CD4+ T-cells, but not PD-1+ CD8+ T-cells, are enriched in immediate proximity to PD-L1+ HRS cells. HRS cells that result in robust expression of the PD-1 ligands that, in turn, engage PD-1 on infiltrating immune cells. 2, 3, 10, 17 Here in, we defined the expression and topographic distribution of PD-L1+ and PD-1+ non-malignant cells in the cHL microenvironment. We characterized the complex cellular TME in cHL using FFPE diagnostic biopsies, simultaneously identifying tens of thousands of cells per sample across large regions of By these methods, we detected PD-L1 expression by at least a subset of HRS cells and
TAMs in all cHLs, as in our previous studies using chromogenic IHC. 10 In all tumors, the majority of tissue PD-L1 was expressed by TAMs. This result is consistent with the observation that TAMs are, in general, far more common than HRS cells. Moreover, we find that TAMs are not randomly distributed; instead PD-L1+ TAMs lie in greater proximity to PD-L1+ HRS cells than PD-L1-TAMs. The biological importance of this microenvironmental 
4 5
Whether PD-L1 expression by TAMs is directly dependent upon the presence of HRS cells is unknown, but the PD-L1+ TAMs are likely programmed as a consequence of the local cytokine milieu. Macrophages demonstrate marked phenotypic plasticity in response to their environment, 18 and the induction of PD-L1 can be mediated by a variety of cytokines,
including IFNγ and GM-CSF. 17, 19, 20 These, and other pro-inflammatory cytokines, are produced by HRS cells, but also the T-cells, natural killer (NK) cells, and myeloid cells within the TME. 19, 21 In this respect, the inflammatory TME of cHL resembles that of certain solid tumors, in which PD-L1 expression by non-malignant cells, including macrophages, is prominent.
22 It will be of interest to micro-dissect and to interrogate regions rich in PD-L1+
5 5
TAMs to characterize the spectrum of cytokines and chemokines that define this specialized niche in greater detail. It will also be of interest to specifically isolate PD-L1+ TAMs to determine whether they express additional phenotypic markers of immunosuppression, such as indoleamine 2,3-dioxygenase 1 (IDO1), which might be targetable and thus synergize with PD-1 blockade. To be effective, PD-L1 must engage PD-1 to inhibit anti-tumor immunity. Despite the marked clinical efficacy of checkpoint blockade, the critical cell populations that express PD-1 and effect anti-tumor immunity in cHL have remained undefined. We examined the expression of PD-1 on T-cells and found that those within the TME of cHL express PD-1 at including those potentially from HRS cells, to CD4+ T-cells by the MHC Class II pathway and, through cross-presentation, to CD8+ T-cells by the MHC Class I pathway. 18 As a consequence, the PD-L1+ TAMs may both promote anti-tumor immunity through antigen presentation to T-cells and to immunosuppression through the engagement of PD-1. Validation of these proposed activities will require functional studies.
8 0
We find that CD4+ T-cells are more often in contact with HRS cells than CD8+ T-cells, consistent with previous studies. 25 Moreover, CD4+ T-cells in contact with HRS cells represent a locally enriched population, whereas CD8+ T-cells do not. Regions with HRS cells can be locally dense in inflammatory cells, a characteristic that can impact spatial 3 8 5
analysis. This is particularly true in the nodular sclerosis subtype compared to the mixed cellularity subtype of cHL. Regardless of subtype, however, we find that PD-L1+ macrophages and CD4+ T-cells are enriched relative to PD-L1-macrophages and CD8+ Tcells in the vicinity of and for contact with HRS cells.
9 0
Similarly, we find that PD-1+ CD4+ T-cells but not PD-1+ CD8+ T-cells in contact with PD-L1+ HRS cells represent a locally enriched population. These observations are of particular interest given that HRS cells more generally express MHC class II than MHC class I. 4, 26 Inactivating somatic mutations in β 2 -microglobulin (β 2 M) is a frequent genetic lesion among HRS cells, and the reduction and loss of expression of the β 2 M / MHC class I complex might 3 9 5 be expected to compromise the ability of HRS cells to engage CD8+ T-cells. 4, 5, 26 The high percentage of cHLs with reduction or complete loss of the β 2 M/ MHC class I protein complex (79%) also indicates that CD8+ T-cells are unlikely to be the only effector cells associated with the efficiency of PD-1 blockade (65-85%) in cHL. 4 
0 0
Indeed, our data suggest that PD-1+ CD4+ T-cells may play a more important role in the anti-tumor response than previously anticipated. Recent studies indicate that CD4+ T-cells may themselves be able to directly kill tumor cells (even those lacking MHC-II), using mechanisms that are more traditionally associated with CD8+ CTLs. 27, 28 In subsequent studies, it will be important to employ additional phenotypic markers to further define the PD-4 0 5
1+ CD4+ T-cell population, including those that identify CD4+ cytotoxic T-cells, Th1-type and Th2-type T-cells, and T-regulatory cells. 29 It will be useful to determine whether these cells express additional immunoregulatory proteins, such as LAG-3, which are also targetable with novel therapies.
30 These data also suggest the importance of determining the distribution and extended functional phenotypes of additional cell lineages, such as NK cells, 4 1 0 NK/T-cells, and γδ T-cells, which can have prominent roles in executing anti-tumor immunity in the absence of MHC class I. 31, 32 The methods described in this study can also be applied to B-cells, plasma cells, and other components of humoral immunity.
0
Finally, the systematic analysis of a large cohort of diagnostic biopsy specimens, preferably 4 1 5 in the context of a clinical trial, will be necessary to determine whether the topological arrangements we observe are associated with response to therapy. In addition, it will be essential to analyze biopsy samples taken from patients while on PD-1 inhibitor therapy to positively identify cell populations that are primarily responsible for HRS cell killing.
2 0
In summary, we have quantified PD-L1:PD-1 interactions in a series of cHL and find a common architectural framework in which the majority of PD-L1 in the microenvironment is derived from TAMs which, like HRS cells, are in extensive contact with PD-1+ T-cells. We propose that HRS tumor cells survive within a specialized cellular niche, an even more localized microenvironment within the broader tumor mass. This expands the overall pool of study tumors, divided into 'mean distance from PD-1+ CD8+ T-cells to the nearest PD-L1+ TAMs' (black) and 'mean distance from PD-1+ CD8+ T-cells to the nearest PD-L1-TAMs' (gray). Tumors are ordered by the distance from PD-1+ CD8+ T-cells to the nearest and PD-L1-TAMs, from highest to lowest; p value (0.005) was calculated by paired t-test. NN= nearest neighbor.
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